A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

NCT07229729 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: SHR-A2102
DRUG: Adebrelimab
DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: Alomnertinib Mesilate
DRUG: Furmonertini Mesilate
DRUG: Osimertinib Mesylate

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.